BridgeBio Pharma Inc. (BBIO) Misses Q3 EPS by 29c

BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q3 EPS of ($1.08), $0.29 worse than the analyst estimate of ($0.79). Revenue for the quarter came in at $4.09 million versus the consensus estimate of $3.62 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• CarMax (KMX) PT Raised to $47 at Morgan Stanley
• KB Home (KBH) Tops Q3 EPS by 16c